Latest:
Dr Ng on Treatment Considerations for Younger Patients With CRC
Kimmie Ng, MD, MPH, discusses treatment considerations for younger patients with colorectal cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kiran K. Turaga, MD
Latest:
Dr. Turaga on Surgery Versus Immunotherapy in Melanoma
Kiran K. Turaga, MD, associate professor of surgery, vice chief, section of general surgery and surgical oncology, director of the Surgical GI Cancer Program and the Regional Therapeutics Program at The University of Chicago Medicine, discusses whether patients vie for immunotherapy versus surgery as treatment for their melanoma.
Klaus Hoeflich, PhD
Latest:
Klaus Hoeflich on Treatment Challenges With Liver Cancer
Klaus Hoeflich, PhD, director of Biology, Blueprint Medicines, discusses diagnosis of liver cancer as well as the treatment challenges associated with the disease during the 10th Annual Conference of the International Liver Cancer Association in Vancouver, Canada.
Kleber Y. Fertrin, MD, PhD
Latest:
Dr. Fertrin on the Potential of Fostamatinib in Chronic ITP
Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).
Koen van Besien, MD, PhD
Latest:
Dr. van Besien on Autologous Stem Cell Transplantation in Hematologic Malignancies
Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.
Kohei Shitara, MD, National Cancer Center Hospital East
Latest:
Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD
Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.
Kohei Shitara, MD, National Cancer Center Hospital East, Japan
Latest:
Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ Adenocarcinoma
Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.
Koichi Takahashi, MD
Latest:
Dr. Takahashi on Biomarker That Predicts Development of Therapy-Related Leukemia
Koichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.
Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP, is the section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center
Latest:
Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer
Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.
Komal L. Jhaveri, MD, FACP
Latest:
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Kosj Yamoah, MD
Latest:
Dr. Yamoah on Racial Disparities in Prostate Cancer
Kosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.
Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center
Latest:
Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma
Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.